Bivalent and bispecific antibodies and their fragments have immense potential for practical application.
VHNQ11-VLD1.3 and VHD1.3-VLNQ11. The fragments were expressed by secretion from bacteria and shown to bind specifically to the hapten and/or antigen. Those with 5-and 15-residue linkers had similar binding afmities to the parent antibodies, but a fragment with the VH domain joined directly to the VL domain was found to have slower dissociation kinetics and an improved affinity for hapten. Diabodies offer a ready means of constructing small bivalent and bispecific antibody fragments in bacteria.
Bivalent and bispecific antibodies have many practical applications, including immunodiagnosis and therapy (1) . Bivalency can allow antibodies to bind to multimeric antigen with great avidity; bispecificity can allow the cross-linking of two antigens-for example, in recruiting cytotoxic T cells to mediate killing of a tumor cell (2) . Bivalent (IgG) antibodies have been derived from hybridomas (3), and bispecific antibodies by fusion of two hybridomas with two different specificities (4) . However, fragments are often preferable to complete antibodies, as the Fc region of antibodies can lead to illegitimate targeting to cells expressing Fc receptors (5) .
Antibody fragments are readily produced by gene technology: the genes encoding antibody variable domains can be derived from hybridomas (6) or from filamentous bacteriophage displaying antibody fragments (7) (for reviews, see refs. 8 and 9). Recombinant Fab and Fv fragments of antibodies can be secreted from bacteria (10, 11) by coexpression of the two chains comprising the heavy-(VH) and light-(VL) chain variable domains. Alternatively the VH and VL domains can be linked on the same polypeptide chain with a flexible spacer stretching between the C terminus of one domain to the N terminus of the other to create single-chain Fv (scFv) fragments (12, 13) . However, Fv, scFv, and Fab fragments each carry a single antigen-binding site.
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Recombinant fragments with two binding sites have been made in several ways-for example, by chemical crosslinking of the hinge cysteine residues (14) or by including a C-terminal peptide that promotes dimerization (15, 16) . Recently we noticed that scFv fragments secreted from bacteria (17) were often present as both monomers and dimers (18) (20) , and the other constructs were cloned in a pUC19-derived expression vector (V1) (21) under control of the lac promoter (P) and with a peptide tag (T) (22) . The variable-domain genes of antibodies NQii (VHA, VLA) and D1.3 (VHB, VLB) have internal Pst I, BstEII, Sac I, and Xho I restriction sites as in refs. 6 and 23: in addition, VLA has an internal Pst I site. The polypeptide linker (Lk) or noncoding region (Ni or N2) between VH and VL of the same chain is marked. Lk consists of a number of repeats (n = 0-3) of Gly-4 --Ser (G4S). Ni includes a ribosome-binding site (rbsl), as described (23), and N2 includes a consensus ribosome-binding site (rbs2), as described (24) . The signal sequences for secretion of fragments into the bacterial periplasm are the pelB signal sequence (Li) (23) and the phage fd gene 3 signal sequence (L2) (25) . Locations of PCR primers 1-8 are shown in constructs III-V. Schematic depiction of protein products, as deduced from Table 1 , is also given. tively) and primer 2 with either primers 6 or 7 or 8 (also encoding no, 5-, or 10-residue linkers, respectively) and digested as above to create PCR fragments a-0, a-S, a-10, b-0, b-5, and b-10. The PCR fragment (c) for providing the noncoding sequence (Ni) in construct VII was generated by using primers 1 and 2 with construct V and digested with BstEII and Asc I.
To make constructs VI, PCR fragments (a-0, a-5, a-10, and a-15) from construct IV were ligated with the corresponding PCR fragment b and the vector fragment III-BstEII/Sac I. To make constructs VII, PCR fragments (a-5 and a-10) from construct IV were likewise ligated with fragment c. Constructs VIII and IX (data not shown) were derived from constructs VI by partial digestion with Pst I or Xho I, respectively, and religation of the vector fragment. Constructs I with 5-, 10-, and 15-residue linkers were likewise generated by BstEII digestion of the corresponding constructs VI. Construct II with 5-residue linker was generated by ligating fragment II-Pst I/Sac I with fragment a-5 that had been cut with Pst I and Sac I. Construct VI (no linker) was digested with Hindlll and partially digested with Xho I and recloned into the phagemid pHEN1 (20) for phage display.
Ligation mixes and transformation were as described (29) . The linker or noncoding regions were sequenced by the dideoxynucleotide method (30) using VENT(exo-) polymerase (New England Biolabs). The nucleotide sequences of each of the constructs are available from the authors on request.
Olgonucleoddes. Primer 1, 5'-GAC TCA TTC TCG ACT GAG CTC ACT TGG CGC GCC TTA TTA CCG TTT GAT CTC GAG CTT GGT CCC introduces an Asc I site and primes at the 3' VL; primer 2, 5'-GTC CTC GCA ACT GGC GCG CCA CAA TTT CAC AGT AAG GAG GTT TAA CTT GTG AAA AAA TTA TTA TTC GCA ATT introduces an Asc I site and a synthetic ribosome-binding site and primes at the 5' phage fd gene 3 signal; primers 3-5, 5'-GAG CCA TCA ATC GAT CTG GTC ACC GTC TCC TCA (GGC GGT GGC GGA TCG)n GAC ATT GAG CTC ACC CAG TCT CCA introduce a linker of 0, 5, and 10 residues, respectively (n = 0,1,2), between VL and VH, include a BstEII site, and prime at 5' VL; primers 6-8, 5'-GAG CCA TCA ATC TCG GAG CTC GAT GTC (CGA TCC GCC ACC GCC) TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC introduce a linker of 0, 5, 10 residues, respectively (n = 0,1,2), between VH and VL, include a Sac I site, and prime at 3' VH.
Expression of Bispecific Fragments. Fragments were prepared from periplasmic lysates (10) or from bacterial supernatants (11) . For detection of fragments binding to HEL or phOx-bovine serum albumin (phOx-BSA), ELISA was done as described (20) . For sandwich-ELISA, plates were coated with HEL and periplasmic lysate or culture supernatant added as above. Binding was detected by using 100 01 of phOx-BSA at 1 pg/ml, followed by 100 M1 of the mouse antibody NQ22.18.7 at 100 ng/ml (31) directed against phOx and peroxidase-conjugated goat anti-mouse immunoglobulin (1:1000; Sigma). All incubations were made in phosphatebuffered saline containing 2% (wt/vol) skimmed milk powder. Immunoblots were as described (20) . Fragments were purified from bacterial supernatants by affinity chromatography on HEL-Sepharose (23) and/or phOx-BSA Sepharose as described (32) .
Binding Affinities. The dissociation kinetics of antibody fragments to HEL and phOx were measured using plasmon surface resonance with BlAcore (Pharmacia BiosensorAB), as described (18) . For detection of fragments with binding activities to both HEL and phOx-BSA, 10 ,1 of periplasmic lysate or affinity-purified fragment was injected onto the HEL-coated sensor chip (see above) with a constant flow of S ul/min and followed immediately by a pulse of 10 A1 of phOx-BSA at 1 mg/ml. The binding affinity of fragments for phOx was measured by fluorescence quench titrations (33) with the hapten 4-raminobutyryl-phOx, as described (34) . 
RESULTS
Fifteen residues are sufficient to stretch from the C terminus of the VH domain to the N terminus of the VL domain of the same chain (see Fig. 1 for schematic of constructs). However, we found that the chains can also pair with each other, as the "bispecific" antibody construct VI with coexpressed cross-over chains (VHA-VLB, VHB-VLA) yielded fragments that bound to both HEL and phOx-BSA (Table 1) . By ELISA, the binding was specific: no binding could be detected to turkey egg lysozyme or BSA, and the binding to phOx-BSA could be inhibited by adding soluble hapten. By contrast, when the cross-over chains were expressed separately (constructs VIII and IX), as expected, they did not bind to either HEL, turkey egg lysozyme, BSA, or phOx-BSA in ELISA; when mixed together in vitro, however, the two chains did associate as detected by binding to HEL and to phOx-BSA and produced :10% of the ELISA signal obtained when the two chains were coexpressed.
We also used shorter linker lengths of5 and 10 residues: the 5-residue linker cannot stretch between VH and VL domains ofthe same chain, but it does allow the formation ofbispecific fragments (Table 1) . Indeed, prompted by a computer graphic model of the dimers (see Discussion), we joined the C terminus of the VH domain directly to the N terminus of the VL domain. Again the fragment bound to both antigens (Table   1 ) and also when displayed on the surface of phage using the phagemid vector pHEN1 (20) (data not shown).
To prove that both antigen-binding sites were located on the same bispecific fragment, we used sandwich-ELISA (Table 1) and also BlAcore to show that the bispecific fragments that had bound to HEL also bound to phOx-BSA. For example, in Fig. 2B , the fragments were injected and bound to the biosensor chip coated with HEL (segment bc). After refractive index changes (segment cd) and some dissociation (segment de), the fragments were seen to bind to injected phOx-BSA [the difference in resonance units (RU) between e and h reflects the amount ofphOx-BSA bound]. As control, FabDl.3 was shown to bind to HEL, but the bound fragments did not bind, in turn, to phOx-BSA (Fig. 2A) .
The sizes of the fragments binding to HEL or hapten were shown to correspond to dimers by fast protein liquid chromatography (FPLC). We loaded lysate containing the antibody fragment on the FPLC column and passed the effluent over a BIAcore sensor chip coated with antigen or hapten. The binding of the fragments was detected (in real time) by an increase in mass at the surface of the chip (18) . The bispecific fragments were found to be similar in size to a chimaeric D1.3 Fab fragment and bound to chips coated with phOx-BSA as well as to HEL-coated chips (Table 1 ). This result indicated that these bispecific fragments must be dimers, formed by association of the two chains.
The sizes of the fragments were also checked by binding of the C-terminal myc tag of the fragments to the monoclonal antibody 9E10 immobilized on the biochip (Table 1) . This format detects fragnents irrespective of whether they have antigen-binding activities and allowed us to show that the single cross-over chains (constructs VIII and IX) (that do not bind antigen) were dimers with short linkers, but monomers with long linkers. Again the bispecific fragnents emerged in a major peak corresponding to a dimer, irrespective of linker length.
We purified bispecific fragments with 5-and 15-residue linkers and also with no linker by affinity chromatography on HEL and then phOx-BSA-Sepharose columns. The yields of the fragments, as detected either by immunoblots using antibody against the c-myc tag or by binding ELISA were improved when cells were transferred to lower temperature (20°C) after induction (35) . After overnight fermentation, most ofthe protein was located in the culture supernatant and after affinity purification yielded fragment at 0.3-1 mg per liter; the yield appears comparable to those reported for scFv or Fab fragments (17, 36) .
We measured the binding affinity for soluble 4-yaminobutyryl-phOx of bispecific fragments purified on HEL by fluorescence quench titration. The results (Table 2) show that the binding affinities of the bispecific fragments with 5-and 15-residue linkers are similar to the parent Fv. However, the fragment with no linker had a 10-fold improved affinity. We also measured the dissociation kinetics of the fragments from phOx-BSA and HEL by BlAcore. The dissociation of the fragment with no linker from phOx-BSA was at least 10-fold slower ( Table 2) .
We also constructed three-chain fragments (Fig. 1 , construct VII), in which a single-chain VHB-VLA is secreted with the two complementary domains VHA and VLB. The fragments were shown to bind both HEL and phOx (Table 1) and to be bispecific, but the chains appeared in fast equilibrium, as on the FPLC the fragments emerged as a single peak between monomer and dimer in size; see ref. 39 for discussion and references.
DISCUSSION
Here we describe the design of bispecific antibody fragments by taking advantage of the intermolecular pairing of VH and (14) or fusion to dimerization peptides (15, 16) . We linked the VH domain of one antibody to the VL domain of another on the same polypeptide chain to create two chains, VHA-VLB and VHB-VLA, that are coexpressed in the same cell and associate to form dimers with two antigenbinding sites on the same molecule. Although we would expect heterodimers, homodimers, and monomers to be formed on cosecretion of both chains from the same bacterium, only the heterodimers bind to antigen and can be isolated by a single round of affinity chromatography.
We chose two antibodies, D1.3 and NQ11, for which the VH and VL domains are known to associate and form a stable Fv fragment (21, 23) . From the FPLC analysis of the bispecific fragments with 15-residue linkers, it appears that dimers predominate in the lysates (Table 1 ). Presumably the favorable interaction between the complementary domains on the two different chains helps drive dimer formation. However, to promote dimerization for antibodies for which the VH and VL domains are more weakly associated (10) , for example in the cross-over chains (constructs VIII and IX), we used short linkers to prevent the VH and VL domains on the same chain from pairing with each other (Table 1) of the VL domain and dispense with the linker polypeptide. Although this would be expected to result in slight clashes between the two VH domains as they pack together, we envisaged that the strain could be relieved by flexibility of the backbone in these regions or by kinking the N-terminal /-strand of the VL domain. Indeed, the fragment with no linker proved to be dimeric and bispecific (Table 1) , lending support to the proposed model. The binding affinity and dissociation kinetics of the fragment for phOx were altered, suggesting that the forced packing of the domains can lead to structural alterations at the antigen-binding site and that it, indeed, might be possible to build "diabodies" in which the antigen binding of the two binding sites is cooperative (or anticooperative).
The structure of diabodies is compact and with short linkers should be rigid. Indeed, it might be possible to introduce disulfide bonds or other contacts at the interface to make more stable fragments. The lack offlexibility is unlikely to compromise the cross-linking of two soluble antigens or of a cell-surface antigen and a soluble antigen. However, for cross-linking of two cells, some flexibility of the surface antigens may be required. Longer linkers should allow greater flexibility for the diabody heads but would also allow pairing within the same chain and formation of monomer fragments. Breaking one of the linkers entirely, as in the three-chain fragment (Fig. 1) , should give highly flexible heads, but it may prove more difficult to keep the three chains tightly associated.
Diabodies represent a class of bivalent and bispecific antibody fragments similar in size to a Fab fragment. Their size should facilitate penetration of tumors and clearance from the serum. Diabodies could be derived from hybridomas (as above) or from variable-domain gene repertoires displayed on phage (for review, see refs. 8 and 9) and should provide a source of human bivalent and bispecific antibody fragments for medical and industrial exploitation.
